Advertisement

Topics

PubMed Journals Articles About "Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines" RSS

19:02 EST 16th December 2018 | BioPortfolio

Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines articles that have been published worldwide.

More Information about "Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines" on BioPortfolio

We have published hundreds of Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines news stories on BioPortfolio along with dozens of Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines Clinical Trials and PubMed Articles about Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines Companies in our database. You can also find out about relevant Safety And Efficacy Study Of RT001 To Treat Moderate To Severe Lateral Canthal Lines Drugs and Medications on this site too.

Showing "Safety Efficacy Study RT001 Treat Moderate Severe Lateral" PubMed Articles 1–25 of 73,000+

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis.

αβ integrin is a validated target in inflammatory bowel disease. This randomized, phase 2b, placebo-controlled, double-blind study evaluated the efficacy and safety of the anti-αβ antibody abrilumab in patients with moderate-to-severe ulcerative colitis (UC) despite treatment with conventional therapies.


Efficacy and safety of acupuncture at a single BL1 acupoint in the treatment of moderate to severe dry eye disease: Protocol for a randomized, controlled trial.

Dry eye disease (DED) is a very common disease. Although several current treatments offer some symptomatic relief, moderate to severe DED is still difficult to cure at present. Acupuncture may be effective for DED via its promotion of tear secretion and ability to improve symptoms, but evidence of its effectiveness is limited. The aim of this study is to evaluate the effect of acupuncture versus artificial tears in moderate to severe DED.

Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.

Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported.


Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis.

Genital psoriasis (GenPs) is a common, debilitating, and difficult to treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist.

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.

The aim of the present meta-analysis was to systematically assess the efficacy of the various treatments available for moderate to severe psoriasis. PubMed and Embase databases were systematically searched to select relevant studies up to February 2015. Odds ratios (ORs) and their 95% confidence intervals (CIs) were used as effect estimates. In addition, the Psoriasis Area and Severity Index (PASI) 50, PASI 75 and PASI 90 responses for the therapies were systematically assessed. A total of 33 randomized con...

Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis.

Adalimumab (Humira ; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor-α approved to treat adults with moderate-to-severe chronic plaque psoriasis.

Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.

 A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n = 801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference = 2.19). Further, IVIG administration was associated with a hi...

Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.

Data on treatment outcomes in patients with psoriasis who have skin of color are limited. Brodalumab has shown efficacy in patients with moderate-to-severe plaque psoriasis.

Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.

Numerous biologics are currently licensed for the treatment of psoriasis, including new drugs targeting interleukin-17 (IL-17) and interleukin-23 (IL-23). This meta-analysis evaluated the short-term (12-16 weeks) efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis. Twenty-one randomized clinical trials met the defined inclusion criteria. Our results showed that Ixekizumab (160 mg wk0 + 80 mg q2w) had the greatest probability of achievi...

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicenter retrospective study.

Ixekizumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety are currently very limited.

Analgesic Efficacy of Intranasal Ketamine Versus Intranasal Fentanyl for Moderate to Severe Pain in Children: A Prospective, Randomized, Double-Blind Study.

This study aimed to compare analgesic efficacy of intranasal (IN) ketamine to IN fentanyl for moderate to severe pain in children in a pediatric emergency department.

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.

Moderate-to-severe atopic dermatitis can be difficult and costly to treat. The long-term health and economic outcomes of a new therapy, dupilumab, have yet to be evaluated. We aimed to identify the cost-effectiveness of dupilumab compared to usual care in moderate-to-severe atopic dermatitis.

Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.

Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E, a mediator involved in the clinical manifestations of allergic asthma. Evidence for its efficacy and safety in the treatment of moderate-to-severe allergic asthma is based primarily on studies in adolescents and adults. However, there is increasing evidence of its utility in children with allergic asthma aged 6-12 years. Areas covered: This article reviews efficacy, safety and effectiveness of omalizumab in the treatmen...

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting consecutive use of potent TCS to 2-4 weeks.

Safety and Efficacy of Remimazolam Compared to Placebo and Midazolam for Moderate Sedation during Bronchoscopy.

While the complexity of flexible bronchoscopy has increased, standard options for moderate sedation medications have not changed in three decades. There is need to improve moderate sedation while maintaining safety. Remimazolam was developed to address shortcomings of current sedation strategies.

Efficacy of tocilizumab in patients with moderate to severe corticosteroid resistant Graves´ orbitopathy: A randomized clinical trial.

To demonstrate the efficacy of the anti- interleukin-6 receptor monoclonal antibody tocilizumab in patients with moderate to severe corticosteroid resistant Graves´ orbitopathy (GO).

Long-term off-label dupilumab in pediatric atopic dermatitis: A case series.

Clinical trials of dupilumab have shown efficacy in treating moderate-to-severe atopic dermatitis (AD) in adult patients. While a phase 2 trial of dupilumab has shown efficacy and safety in children, the medication awaits Food and Drug Administration (FDA) approval, and off-label use is limited by dosing currently available to adults. We present this case series to describe the efficacy and safety profile of off-label dupilumab use in six pediatric patients treated by one provider in a private practice.

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

To evaluate efficacy, endometrial safety, and overall safety of a single-capsule 17β-estradiol-progesterone for treating menopausal moderate-to-severe vasomotor symptoms.

Therapeutic hypothermia for moderate and severe hypoxic ischaemic encephalopathy in newborns using low-cost devices - ice packs and phase changing material.

Different methods have been used for therapeutic hypothermia for neonates with moderate-to-severe hypoxic ischaemic encephalopathy (HIE). As standard cooling devices are expensive, there is a need to establish the safety and efficacy of low-cost devices such as ice packs (IP) and phase changing material (PCM).

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Background Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma. Methods We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a 2:2:1:1 ratio to receive add-on subcutaneous dupilumab at a dose of 200 or 300 mg every 2 weeks or matched-volume placebos for 52 weeks. The primary end points were the annualized rate of se...

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Risankizumab, an anti-interleukin 23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn's disease. Here we aimed to assess the efficacy and safety of extended intravenous induction and subcutaneous maintenance therapy with risankizumab.

A Chinese herbal medicine preparation (PTQX) for children with moderate to severe atopic eczema: a pilot RCT.

Atopic eczema (AE) or atopic dermatitis is a chronic and relapsing inflammatory skin disease. The prevalence and burden of AE are increasing globally. Systemic immunomodulating medications including corticosteroids or immunosuppressive drugs are efficacious agents for difficult-to-treat or refractory moderate or severe AE, but are not used routinely due to safety concerns. Some AE patients reported using complementary and alternative medicines including Chinese herbal medicine (CHM). A Cochrane systematic r...

A systematic review on the off-label use of montelukast in atopic dermatitis treatment.

Background Atopic dermatitis (AD) is the most common form of eczema. As leukotriene mediators are involved in the inflammatory phase of atopic dermatitis, montelukast has been suggested as a possible therapy. Aim of the review To evaluate the safety and efficacy of montelukast off-label use for the treatment atopic dermatitis. Method A search was performed from database inception until March 2018 in six electronic databases for randomized-controlled-trials examining the use of montelukast for AD. Results...

Psychological distress and completed suicide in Japan: A comparison of the impact of moderate and severe psychological distress.

It has already been established that severe psychological distress is a major risk factor for completed suicide. However, the impact (population attributable fraction; PAF) of moderate psychological distress on completed suicide has not been clarified. The present study investigated the association between various severities of psychological distress and completed suicide. We analyzed follow-up data covering a 7.3-year period (2006-2014) for 43,473 adults (aged ≥ 40 years) participating in a communi...

Efficacy of autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement. A prospective controlled clinical study.

To assess and compare the efficacy and safety of autogenous tooth roots (TR) and autogenous bone blocks (AB) for lateral alveolar ridge augmentation and two-stage implant placement.


Advertisement
Quick Search
Advertisement
Advertisement